RxDoctor Payments Data

Kerri Rossi, APRN

Family · Danbury, CTNPI 1083089841

Payments from drug & device makers

$941in general payments, 2019–2025

Across 23 payments — averaging $40.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$281
  • GSK$209
  • Sanofi$207
  • Regeneron Healthcare Solutions, Inc.$74
  • Insmed, Inc.$33
  • E.r. Squibb & Sons, L.L.C.$30
  • plus $107 from 4 others

What the payments were for

  • Food & beverage$86892%
  • Education$748%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$941 in reported general payments places this provider in the 70th percentile of 1,596 family providers in Connecticut.

See all family providers in Connecticut

Medicare billing

Part B allowed, 2024
$48,793
Medicare patients
233
Services billed
762

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter216$204,773
Breo ElliptaFluticasone/Vilanterol177$106,783
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr128$102,299
NucalaMepolizumab21$84,562
XolairOmalizumab18$56,490
Dupixent PenDupilumab12$53,123
Incruse ElliptaUmeclidinium Bromide56$28,250
SymbicortBudesonide/Formoterol Fumarate69$23,859
Arnuity ElliptaFluticasone Furoate73$21,451
Stiolto RespimatTiotropium Br/Olodaterol Hcl21$18,892
EliquisApixaban12$16,006
Spiriva RespimatTiotropium Bromide15$15,574
Spiriva HandihalerTiotropium Bromide11$13,289
Fluticasone-VilanterolFluticasone/Vilanterol18$12,594
Albuterol Sulfate HfaAlbuterol Sulfate287$9,277

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Nucala, Incruse Ellipta$209$548,119671 claims
AstraZenecaSymbicort$281$23,85969 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,596 family providers in Connecticut.

Other family in Danbury

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →